Active Cancer NIHR-supported project Digestion, Kidneys & Other Organs
A Phase II, Multi-centre, Open label, Randomised Study to Evaluate the Anti-tumour Activity of Roginolisib (IOA-244) in Patients with Advanced/Metastatic Ocular/Uveal Melanoma
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Matthew Wheater (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
A phase II, open-label, multicenter, randomized study of the efficacy and safety of RO7198457 in combination with pembrolizumab versus pembrolizumab in patients with previously untreated advanced melanoma
A translational phase II study of Single agent Olaparib in the treatment of advanced oesophagogastric cancer
CRUK/13/007: A randomised phase two-arm phase II study of Trametinib alone and in combination with GSK214795 in patients with advanced uveal melanoma (International Rare Cancers Initiative Trial - IRCI 005) (Supported by Stand Up To Cancer)
A randomised phase II feasibility study of INTERmittent versus continuous dosing of oral targeted combination therapy In patients with BRAFV600 mutant stage 3 unresectable or metastatic Melanoma
A multicentre randomised open-label phase III study of stereotactic radiosurgery, in addition to standard systemic therapy for patients with metastatic melanoma or newly diagnosed metastatic NSCLC and asymptomatic or oligo-symptomatic brain metastases.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know